Role of leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity

Alerjik rinit ve astım komorbiditesinin tedavisinde lökotriyen antagonisti ve antistaminiklerin rolü

Ayşe Baççoğlu¹, Arzu Yorgancioğlu², Cemal Cingi³, Çağlar Çuhadaroğlu⁴

¹Department of Immunology and Allergy, Erzurum Region Training and Research Hospital, Erzurum, Turkey
²Department of Chest Diseases, Celal Bayar University Medical Faculty, Manisa, Turkey
³Department of Otorhinolaryngology, Osmangazi University Medical Faculty, Eskisehir, Turkey
⁴Department of Chest Diseases, Aşkabadem University, İstanbul University

Abstract
Leukotriene receptor antagonists and antihistamines are efficient in reducing symptoms of allergic rhinitis and asthma when used alone or in combination. In patients with allergic rhinitis, H1-antihistamines prevent and relieve the sneezing, itching, rhinorrhea, and nasal congestion that characterize the early and the late response to allergen. Leukotriene antagonist such as montelukast may be an alternative treatment for mild persistent asthma as monotherapy where inhaled corticosteroid cannot be administered or alternative to long-acting beta agonist as an add-on therapy to ICS for moderate to severe persistent asthma. Although montelukast is an effective drug in allergic rhinitis indicated as monotherapy, but widely recommended as adjunct to antihistamine or intranasal corticosteroid. Antileukotriene agents are also widely used in the treatment of pediatric asthma. In children, maintenance treatment with inhaled corticosteroids in pure episodic (viral) wheeze was ineffective, but maintenance as well as intermittent montelukast was shown to have an efficient role in both episodic and multi trigger wheeze. Furthermore, their advantage to inhaled corticosteroids is that leukotriene receptor antagonists do not affect short-term lower leg growth rate in prepubertal children.

Key words: Leukotriene antagonist; antihistamines; allergic rhinitis; asthma.

Özet

Anahtar sözcükler: Lökotrien antagonistı; antihistaminik: alerjik rini- nit; astma.

Allergy is a reaction with inflammatory cell infiltration in the target organ which allergen has been found to cause the pathology.¹ ² Allergens cause an immunoglobulin (Ig)
early as well as the late phase of the allergic reaction. These and other mediators lead to vasodilatation, increased permeability, and bronchoconstriction, which result to rhinitis, asthma and urticaria.\[3\] Allergic rhinitis has a wide range of comorbidities such as asthma, rhinosinusitis, dermatitis, and conjunctivitis.\[4\]

**The Link Between Allergic Rhinitis and Asthma**

About 70-90% of asthmatics have rhinitis, and 10-40% of rhinitics are reported to have asthma.\[1,2\] Allergen-specific challenge of rhinitic patients also causes an increased response of bronchi with the presence of eosinophilia in secretions from the nose and sputum.\[6\] Non-allergic diseases of the nose, such as common cold or sinusitis, can often lead to the development or worsening of asthma symptoms.\[8\] In conclusion, there is an increased risk that asthma will develop in patients with either allergic rhinitis or non-allergic persistent rhinitis, thus uncontrolled allergic rhinitis can lead to worsening of co-existing asthma.\[1,6\] Furthermore, having comorbidity in rhinitis or asthma also impairs quality of life.\[7\] Therefore a strategy should combine the treatment of upper and lower airways in terms of efficacy and safety. There are three major classes of commonly used allergicrhinitis medications-intranasal corticosteroids, antihistamines, and antileukotrienes.\[1\] Combination of antihistamine and montelukast is a therapeutic option in allergic rhinitis that would benefit from successful inhibition of persistent inflammation.\[8\]

**Antihistamines**

Antihistamines downregulate allergic inflammation by interfering with histamine action at histamine-1 (H1) receptors on sensory neurons, and small blood vessels.\[9\] H1-antihistamines are functionally classified into 3 groups. First generation antihistamines have poor H1 receptor selectivity, and cross the blood brain barrier, whereas second and third generation antihistamines are highly selective for the H1 receptor, and do not cross the blood brain barrier.\[10\] Third generation antihistamines are the active enantiomer (levocetirizine) or metabolite (desloratadine and fexofenadine) derivatives of second generation drugs (cetirizine, loratadine, terfenadine). They intended to have increased efficacy with fewer adverse drug reactions. Some antihistamines, such as fexofenadine, have a strong interaction with grapefruit juice.\[11\] The overall safety profiles of antihistamines such as levocetirizine and desloratadine were similar to placebo in children and adults, which had been confirmed in randomized, placebo-controlled.\[10\]

**The Role of Antihistamines in Allergic Rhinitis and Asthma**

H1-antihistamines are widely used in the treatment of allergic and nonallergic disorders.\[13\] In patients with allergic rhinitis, second generation H1-antihistamines prevent and relieve the sneezing, itching, rhinorrhea, and nasal congestion that characterize the early and the late response to allergen.\[10\] In the treatment of allergic rhinitis, oral H1-antihistamines are more efficacious than chromones; but less efficacious than nasal glucocorticoids.\[10\] In a study done comparing nasal H1-antihistamine and nasal glucocorticoid in patients with allergic and nonallergic rhinitis, azelastine was as effective as triamcinolone in improving nasal symptoms; sleep symptoms and quality of life.\[12\]

H1-antihistamines are not medications of choice in asthmatic patients. However, comorbidity of asthma and allergic rhinitis is very high (80%) and they have clinically relevant antiasthmatic properties by controlling rhinitis.\[11\] Confirming this statement, it was shown that antihistamines have reduced asthma symptoms in patients with seasonal allergic rhinitis when given alone or in combination with an antileukotriene.\[14\] The early treatment of atopic child (ETAC) study also showed that the onset of asthma was prevented by continuous antihistamine treatment.\[11\] Therefore, H1-antihistamines appear to provide indirect benefit in patients with concomitant asthma and allergic rhinitis.

**Antileukotrienes**

Leukotriene modifiers represent the first mediator specific therapeutic option for rhinitis and asthma.\[16\] Antileukotrienes are classified in two groups; cysteinyll leukotriene receptor antagonists (LTrAs) – zafirlukast, pranlukast, and montelukast – block the leukotriene receptor and thus block the end organ response of leukotriene.\[14\] Zafirlukast is a leukotriene (L'T) D4 receptor antagonist and is efficient in LTD4 induced bronchoconstriction, early and late responses, exercise challenge, cold induced asthma, and chronic asthma. Leukotriene synthesis inhibitors – zileuton – block the biosynthesis of cysteinyll leukotrienes. Zileuton is a 5-lipoxygenase inhibitor and is used in exercise, cold, aspirin induced bronchial hyper-responsiveness. There are also FLAP inhibitors, which are not approved by food and drug administration, but they have benefits in early and late allergic responses and cold induced asthma.\[14\]

Montelukast is the prevalent used antileukotriene, and is the only such agent approved for use in pediatric
patients.\[17\] It does not have any documented interactions with food, nonetheless, recently an interaction was reported that showed an increase of plasma concentration of montelukast after excessive grapefruit juice intake due to cytochrome p450.\[18\] Patient satisfaction and compliance was better with montelukast than inhaled antiinflammatory agents due to oral, and once a day administration.\[19\] Furthermore, it provides a safe and effective additional antiinflammatory treatment option not only for asthma and rhinitis but also for chronic obstructive disease.\[19\]

**The Role of Antileukotrienes in Allergic Rhinitis and Asthma**

Presently, the available evidence does not support routine use of oral LTRAs in acute asthma.\[21\] However, trials of intravenous treatment of LTRAs in adults and children demonstrated a reduction in the risk of hospital admission which was not quite statistically significant, and a statistically significant small increase in FEV1 was determined in the adults, but not in children.\[19\]

At present, antileukotrienes serve as alternative monotherapy to inhaled corticosteroids in the management of mild persistent asthma in adults and children.\[21\] As monotherapy in adults and children with persistent asthma and moderate airway obstruction, inhaled corticosteroids were superior in most secondary outcomes including exacerbation requiring hospital admission, FEV1 and other lung function parameters, asthma symptoms, nocturnal awakenings, rescue medication use, symptom-free days, the quality of life, parents’ and physicians’ satisfaction.\[22\] Furthermore, antileukotriene therapy was associated with increased risk of withdrawals due to poor asthma control and exacerbation requiring systemic corticosteroids. On the other hand, asthma control may remain suboptimal when relying on inhaled corticosteroids because of problems with compliance, poor inhaler technique and concerns about the side effects of steroids.\[17\] In this case, montelukast may be an alternative treatment for mild persistent asthma as monotherapy where inhaled corticosteroid cannot be administered.

Leukotriene receptor antagonists have indication as add on therapy to inhaled steroids as alternative to long acting beta2 agonists in moderate-severe persistent asthma.\[21\] In comparison of long acting beta2 agonists as an add-on therapy to inhaled corticosteroid in patients with moderate to severe persistent asthma, montelukast was found to be less efficacious and less cost-effective.\[21\] However, LTRAs might decrease small airway/alveolar sites of inflammation when combined to inhaled corticosteroid therapy which was shown by a higher reduction in fractional exhaled nitric oxide levels—a marker of inflammation— in combination therapy than inhaled corticosteroid alone.\[21\]

Antileukotriene agents are also widely used in the treatment of pediatric asthma. In children maintenance treatment with inhaled corticosteroids in pure episodic (viral) wheeze was ineffective, but maintenance as well as intermittent montelukast was shown to have an efficient role in both episodic and multi trigger wheeze.\[24\] Furthermore, their advantage to inhaled corticosteroids is that LTRAs do not affect short-term lower leg growth rate in prepubertal children.\[23\]

Leukotriene receptor antagonists have particular benefit for patients with exercise-induced asthma. They can be used prior to exercise to prevent exercise-induced bronchoconstriction just as short or long acting beta2 agonists.\[26\]

Leukotriene receptor antagonists have beneficial effects in aspirin-sensitive rhinitis and asthma besides corticosteroids.\[21,27\] Aspirin sensitivity is characterized by intense eosinophilic inflammation of nasal and bronchial tissues in non-atopic patients with chronic rhino-sinusitis and/or nasal polyps.\[21\] Montelukast reduces peripheral blood eosinophilia, but do not affect tissue eosinophilia.\[27\]

Corticosteroids are the mainstay of treatment in allergic rhinitis, however montelukast may be considered as an additional agent especially in treatment of patients with impaired quality of life and it may be used to reduce nasal symptom scores and to improve the disease-specific quality of life.\[21,29,26\] Although montelukast is an effective drug in allergic rhinitis to decrease nasal inflammation and limit nasal congestion, sneezing, and rhinorrhea, indicated as monotherapy, but widely recommended as adjunct to antihistamine or intranasal corticosteroid.\[16\] These agents primarily help with congestion and are particularly useful in asthmatics where they may have the double benefit of improving lower airway disease.

In nasal polyposis, surgery and corticosteroids is the mainstay of treatment.\[30\] However, there exists an increased leukotriene production in nasal polyps, and antileukotrienes, especially montelukast, may represent a potential effective therapy.\[30,31\] In a recent study it was shown that montelukast therapy might have a clinical benefit as an adjunct to nasal steroids in subjects with nasal polyposis accompanying bronchial asthma in means of rhinosinusitis disability index scores.\[32\]
Antileukotrienes are also used in allergen specific immunotherapy concomitantly to prevent local and systemic reactions. Studies showed that both antihistamines and montelukast pretreatment have been shown to reduce anaphylactic side effects when used alone which improved patients’ adherence to specific immunotherapy. \[39\]

**Combination of H1-Antihistamine and Cysteinyl Leukotriene Receptor Antagonist**

Both antihistamines and antileukotrienes have been found to be useful when used alone in allergic rhinitis and asthma. Combination of both drugs showed a synergistic effect in treating seasonal allergic rhinitis. \[14\] The first combination treatment studies with montelukast was done with second generation antihistamines such as loratadine and cetirizine, followed by combinations with third generation antihistamines-fexofenadine, desloratadine, levocetirizine. Then fixed combinations of montelukast-levocetirizine and montelukast-desloratadine tablets were aiming to increase the quality of life of the patients.

**The Role of Combination of H1-Antihistamine and Cysteinyl Leukotriene Receptor Antagonist in Allergic Rhinitis**

It is reported that antihistamines and antileukotrienes have been found to be useful when used alone in allergic rhinitis and asthma. Combination of antihistamines and antileukotrienes showed a synergistic effect in treating seasonal allergic rhinitis. But further studies are needed for fixed combinations. In a study of patients with seasonal allergic rhinitis showed that neither loratadine nor montelukast, when used on their own, conferred any benefit in terms of improving day-time nasal symptoms, while day-time nasal symptoms were significantly improved when the two drugs were combined. \[34\] Similarly, montelukast plus cetirizine treatment started 6 weeks before the pollen season was effective in preventing allergic rhinitis symptoms and reduces allergic inflammation in nasal mucosa during natural allergen exposure. \[36\] In persistent allergic rhinitis, montelukast, levocetirizine, desloratadine, and the montelukast/antihistamine combinations significantly improved nasal symptoms during the first 24 hours, but improvement at the end of 6 weeks was significantly greater than that achieved on the 1st day of therapy in patients treated with montelukast alone or in combination therapy with the antihistamine. \[37\] In a 32-week randomized study, placebo, montelukast, desloratadine and levocetirizine significantly improved quality of life, but combining montelukast with either levocetirizine or desloratadine gave additional benefits in comparison to each agent in patients with persistent allergic rhinitis. \[38\] Another study showed that, fexofenadine with montelukast combination therapy was more effective than fexofenadine alone in means of allergic rhinitis symptoms, and rhinomanometry results. \[39\]

Some studies reported no further benefit of combination of montelukast and antihistamine than used alone. Fexofenadine as monotherapy was shown to be equally effective as the combination of montelukast and levocetirizine in improving nasal peak flow and controlling symptoms in seasonal allergic rhinitis and asthma. \[40\] Similarly, a study of patients with seasonal allergic rhinitis found that the combination of loratadine and montelukast was no more effective than montelukast alone on day-time or night-time symptoms. \[41\] Furthermore, similar efficiency of monotherapy and combined therapy of antihistamine or antileukotriene was only found in patients with mild persistent rhinitis, and further studies are required to evaluate putative additivity of response with combined therapy in more severe patients.

**The Role of H1-Antihistamine and Cysteinyl Leukotriene Receptor Antagonist in Asthma**

In asthma, montelukast is given on regular basis to reduce eosinophilic airway inflammation. Addition of the antihistamine can amplify the early and late anti-inflammatory activities of montelukast. \[37\] Combination therapy synergistically inhibits the allergen-induced early asthmatic response, and montelukast also suppresses the allergen-induced late asthmatic response. \[17,37\] As a result combination of antihistamine and LTRAs has an effect that is greater than that of either drug given alone. \[37\]

In a randomized study of two combinations of antihistamine plus [in patients with seasonal allergic rhinitis and mild intermittent asthma, after 2 weeks cetirizine might exert more beneficial activity than desloratadine when added to montelukast as shown by the reduced nasal symptoms, inflammatory cells and cytokines in nasal lavage. In this study antileukotriene-antihistamine combinations were only effective in relieving nasal symptoms, but control of rhinitis may have a positive effect on asthma later. In a randomized study of patients with mild-to-moderate atopic asthma, after 26 hours of the treatment, early response to inhaled allergen was unchanged after desloratadine therapy and partially inhibited with montelukast therapy, whereas combination of desloratadine
Antileukotriene-antihistamine combinations when used as either monotherapy or add-on therapy to local corticosteroids have been shown to attenuate the response to adenosine monophosphate—a sensitive marker of inflammatory process in airways further reinforcing the concept of the united allergic airway. The putative benefits of such combination therapy certainly become evident when looking at concomitant effects on asthma control in patients who have concomitant allergic rhinitis.

In a multicentric randomised double-blind crossover study comparing single-dose placebo, 5 mg desloratadine, 10 mg montelukast and the combination administered 2 h prior to allergen inhalation challenge showed that single-dose co-administration of desloratadine and montelukast 2 h prior to allergen inhalation clinically abolished the late atopic asthmatic response in means of eosinophil recruitment when looking at concomitant effects on asthma control. Treatment of montelukast + desloratadine, montelukast alone and placebo were given 10-14 h prior to allergen inhalation challenge with mannitol. Both montelukast/desloratadine and montelukast compared to placebo, shortened recovery following both challenges. Montelukast was not significantly different from placebo montelukast/desloratadine combination on AHR and recovery time, highlights the relative roles of histamine in initiating the bronchoconstrictor response and cysteinyleukotrienes in sustaining it.

In conclusion, antihistamines and antileukotrienes as monotherapy significantly improves nasal symptoms, with the expectation of additional benefit conferred by combination therapy.

Conflict of Interest: No conflicts declared.

References
Role of leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity


This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) Licence (https://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.